# US 2023/0295560 A1 · Synthetic ecologies for drug discovery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0295560 A1
- Document ID: US20230295560A1
- Status: Published application
- Kind: A1
- Application number: 18/054,714
- Filed: 2022-11-11
- Published: 2023-09-21
- Earliest claimed: 2021-11-11
- Assignees: William Marsh Rice University
- Applicants: William Marsh Rice University
- Inventors: Yousif SHAMOO; Heer MEHTA; Ramya Ganiga PRABHAKAR; Seokju SEO
- Web page: https://patentgrep.com/patent/US20230295560A1

## CPC

- C12N 1/20: Bacteria; Culture media therefor
- C12N 1/205: Bacterial isolates
- C12M 23/16: {Microfluidic devices; Capillary tubes (integrated microfluidic structures B01L3/5027; microreactors B01J19/0093)}
- C12N 1/145: Fungi isolates
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- C12R 2001/07: Bacillus
- C12R 2001/185: Escherichia
- C12R 2001/22: Klebsiella
- C12R 2001/365: Nocardia
- C12R 2001/38: Pseudomonas
- C12R 2001/44: Staphylococcus
- C12R 2001/465: Streptomyces
- C12R 2001/80: Penicillium
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The present disclosure is directed to composition and methods for use in drug screening methods. The identification of microbial strains producing antibiotics effective against multi-drug resistant bacterial pathogens using microfluidics and co-encapsulation of predator and prey strains permits rapid and multiplexed assessment of new antibiotics for emerging bacterial pathogens including those resistant to multiple existing antibiotics.

## Claims

### Claim 1

A microenvironment comprising a single predator strain of an antibiotic-producing microbe and a single strain of a multi-drug resistant (MDR) bacterial pathogen.

### Claim 2 (depends on 1)

The microenvironment of claim 1, wherein said microenvironment is a water-in-oil (W/O) microdroplet.

### Claim 3 (depends on 2)

The microenvironment of claim 2, wherein said microdroplet (a) is about 10-200 μm in diameter or about 100 μm in diameter; and/or (b) comprises 10 or fewer than microbial cells, such as 1 or 2 predator strain cells and 1 to 10 MDR pathogen cells.

### Claim 4 (depends on 1)

The microenvironment of claim 1, wherein said predator strain produces a fluorescent signal and/or said MDR bacterial pathogen produces a fluorescent signal.

### Claim 5 (depends on 4)

The microenvironment of claim 4, wherein said predator strain produces a first fluorescent signal and said MDR bacterial pathogen produces a second fluorescent signal, said first and second fluorescent signals being optically distinguishable.

### Claim 6 (depends on 1)

The microenvironment of claim 1, wherein said predator strain is a culturable bacterium is selected from the group of wild or cultured isolates belonging to the genus Streptomyces, Bacillus, or Nocardia or a fungus belonging to the genus Penicillium.

### Claim 7 (depends on 1)

The microenvironment of claim 1, wherein said MDR bacterial pathogen is selected from the group consisting of Pseudomonas, Nocardia, Escherichia, Klebsiella, Staphylococcus, Acinetobacter, Francisella, or Enterococcus.

### Claim 8 (depends on 1)

The microenvironment of claim 1, wherein said microenvironment is disposed in a bacterial growth chamber containing bacterial growth media.

### Claim 9 (depends on 8)

The microenvironment of claim 8, wherein said bacterial growth chamber comprises additional microenvironments each comprising said predator strain and said MDR bacterial pathogen.

### Claim 10 (depends on 1)

The microenvironment of claim 1, wherein said predator strain has been subjected to a mutagen, such as N-methyl-N′-nitro-N-nitrosoguanidine.

### Claim 11

A method of co-culturing a single predator strain of an antibiotic-producing microbe and a single strain of a multi-drug resistant (MDR) bacterial pathogen comprising:
(a) microencapsulating a single predator strain of an antibiotic-producing microbe and a single strain of a MDR bacterial pathogen to create a microenvironment; and
(b) culturing said microenvironment in a bacterial growth chamber containing bacterial growth medium.

### Claim 12 (depends on 11)

The method of claim 11, wherein said microenvironment is a water-in-oil (W/O) microdroplet, such as generated by mixing aqueous and oil phases, in particular being generated through microfluidic processing.

### Claim 13 (depends on 12)

The method of claim 12, wherein said microdroplet (a) is about 10-200 μm in diameter or about 100 μm in diameter; and/or (b) comprises 10 or fewer than microbial cells, such as 1 or 2 predator strain cells and 1 or 2 MDR pathogen cells.

### Claim 14 (depends on 11)

The method of claim 11, wherein said predator strain produces a fluorescent signal and/or said MDR bacterial pathogen produces a fluorescent signal.

### Claim 15 (depends on 14)

The method of claim 14, wherein said predator strain produces a first fluorescent signal and said MDR bacterial pathogen produces a second fluorescent signal, said first and second fluorescent signals being optically distinguishable.

### Claim 16 (depends on 11)

The method of claim 11, further comprising assessing the relative amounts of said predator strain and said MDR bacterial pathogen after culture.

### Claim 17 (depends on 16)

The method of claim 16, further comprising isolating said microenvironment when the relative amount of predator strain present is greater than said MDR bacterial pathogen, such as by fluorescence activated sorting.

### Claim 18 (depends on 17)

The method of claim 17, further comprising obtaining said predator strain from said isolated microenvironment.

### Claim 19 (depends on 11)

The method of claim 11, wherein said predator strain is a culturable bacterium is selected from the group wild or cultured isolates belonging to the genus Streptomyces, Bacillus, or Nocardia or a fungus belonging to the genus Penicillium.

### Claim 20 (depends on 11)

The method of claim 11, wherein said MDR bacterial pathogen is selected from the group consisting of Pseudomonas, Nocardia, Escherichia, Klebsiella, Staphylococcus, Acinetobacter, Francisella, or Enterococcus.

### Claim 21 (depends on 11)

The method of claim 11, wherein said bacterial growth chamber comprises additional microenvironments each comprising said predator strain and said MDR bacterial pathogen.

### Claim 22 (depends on 11)

The method of claim 11, wherein said predator strain has been subjected to a mutagen.

### Claim 23 (depends on 11)

The method of claim 11, wherein culturing is performed for about 24 hours to about 72 hours, or for about 48 hours, optionally at 30° C.

### Claim 24 (depends on 17)

The method of claim 17, further comprising:
(c) decapsulating said selected predator strain;
(d) re-microencapsulating said selected predator strain and a single strain of a MDR bacterial pathogen to create a second microenvironment;
(e) culturing said second microenvironment in a bacterial growth chamber containing bacterial growth medium;
(f) assessing the relative amounts of said predator strain and the MDR bacterial pathogen of step (d) after culture;
(g) isolating said second microenvironment when the relative amount of predator strain present is greater than said MDR bacterial pathogen; and
(h) obtaining said predator strain from said isolated second microenvironment.

### Claim 25 (depends on 24)

The method of claim 24, wherein steps (c)-(h) are further repeated, such as for a total of 10 cycles.

### Claim 26 (depends on 25)

The method of claim 25, wherein a further mutagenesis step is applied to the predator strain after one or more cycles.

### Claim 27 (depends on 25)

The method of claim 25, further comprising changing microenvironment volume and/or ratio of said predator strain to said MDR bacterial pathogen between cycles.

### Claim 28 (depends on 11)

The method of claim 11, wherein step (b) is performed using a microfluidic system employing flow-focusing geometry.

### Claim 29 (depends on 16)

The method of claim 16, wherein said assessing is performed using a microfluidic system employing flow-focusing geometry.

### Claim 30 (depends on 17)

The method of claim 17, wherein said isolating is performed using a microfluidic system employing flow-focusing geometry.
